Highlights of This Issue 845

REVIEW
847  PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
Sandip Pravin Patel and Razelle Kurzrock

SMALL MOLECULE THERAPEUTICS
857  Preclinical Pharmacological Evaluation of Letrozole as a Novel Treatment for Gliomas
Nimita Dave, Lionel M.L. Chow, Gary A. Gudelsky, Kathleen LaSance, Xiaoyang Qi, and Pankaj B. Desai

865  Functional Genetic Screen Identifies Increased Sensitivity to WEE1 Inhibition in Cells with Defects in Fanconi Anemia and HR Pathways
Marieke Aarts, Ilirjana Bajrami, Maria T. Herrera-Abreu, Richard Elliott, Rachel Brough, Alan Ashworth, Christopher J. Lord, and Nicholas C. Turner

877  ATF4 Gene Network Mediates Cellular Response to the Anticancer PARP Inhibitor YM3-56 in Triple-Negative Breast Cancer Cells
Shu Wang, Xiangyun Amy Chen, Jing Hu, Jian-kang Jiang, Yunfei Li, Ka Yim Chan-Salis, Ying Gu, Gong Chen, Craig Thomas, B. Franklin Pugh, and Yanning Wang

889  The Combination of the PARP Inhibitor Rucaparib and 5FU Is an Effective Strategy for Treating Acute Leukemias
Maria Vittoria Verga Falzacappa, Chiara Ronchioni, Mario Fareta, Ilaria Iacobucci, Andrea Ghelli Luserna Di Rorà, Giovanni Martinelli, Ludin Hinrich Meyer, Klaus-Michael Debatin, Stefania Orecchioni, Francesco Bertolini, and Pier Giuseppe Pelici

899  Magnetic Resonance Spectroscopy for Detection of Choline Kinase Inhibition in the Treatment of Brain Tumors
Manoj Kumar, Sean P. Areluckas, Sona Saksena, Gaurav Verma, Ranjit Iyterah, Stephen Pickup, Anatoliy V. Popov, Edward J. Delikatny, and Harish Poptani

NEW BLOCKING ANTIBODIES AGAINST NOVEL AGR2–C4.4A PATHWAY REDUCE GROWTH AND METASTASIS OF PANCREATIC TUMORS AND INCREASE SURVIVAL IN MICE
Thiruvengadam Arumugam, Deleng Deng, Laura Bover, Huamin Wang, Craig D. Logsdon, and Vijaya Ramachandran

LARGE MOLECULE THERAPEUTICS
941  New Blocking Antibodies against Novel AGR2–C4.4A Pathway Reduce Growth and Metastasis of Pancreatic Tumors and Increase Survival in Mice
Thiruvengadam Arumugam, Deleng Deng, Laura Bover, Huamin Wang, Craig D. Logsdon, and Vijaya Ramachandran
Tumor Cells Chronically Treated with a Trastuzumab–Maytansinoid Antibody–Drug Conjugate Develop Varied Resistance Mechanisms but Respond to Alternate Treatments

Nonclinical Safety Evaluation of VX15/2503, a Humanized IgG4 Anti-SEMA4D Antibody
John E. Leonard, Terrence L. Fisher, Laurie A. Winter, Chad A. Cornelius, Christine Reilly, Ernest S. Smith, and Maurizio Zauderer

A Novel Neutralizing Antibody Targeting Pregnancy-Associated Plasma Protein-A Inhibits Ovarian Cancer Growth and Ascites Accumulation in Patient Mouse Tumorgrafts
Marc A. Becker, Paul Haluska Jr, Laurie K. Bale, Claus Oxvig, and Cheryl A. Conover

The IGF-Trap: Novel Inhibitor of Carcinoma Growth and Metastasis
Ni Wang, Roni F. Rayes, Seyyed Mehdy Elahi, Yifan Lu, Mark A. Hancock, Bernard Massie, Gerald E. Rowe, Hafida Aomari, Sazzad Hossain, Yves Durocher, Maxime Pinard, Sébastien Tabaries, Peter M. Siegel, and Pnina Brodt

Dual PI3K/mTOR Inhibitors Induce Rapid Overactivation of the MEK/ERK Pathway in Human Pancreatic Cancer Cells through Suppression of mTORC2
Heloisa P. Soares, Ming Ming, Michelle Mellion, Steven H. Young, Liang Han, James Sinten-Smith, and Enrique Rozengurt

Targeting Integrin-Linked Kinase Suppresses Invasion and Metastasis through Downregulation of Epithelial-to-Mesenchymal Transition in Renal Cell Carcinoma
Kyung Seok Han, Na Li, Peter A. Raven, Ladan Fazli, Susan Ettinger, Sung Joon Hong, Martin E. Gleave, and Alan I. So

Targeted Blockade of JAK/STAT3 Signaling Inhibits Ovarian Carcinoma Growth
Galina Gritsits, Fang Xiao, Shane W. O’Brien, Rashid Gabbasov, Marisa A. Maglaty, Ren-Huan Xu, Roshan J. Thapa, Yan Zhou, Emmanuelle Nicolas, Samuel Litwin, Siddharth Balachandran, Luis J. Sigal, Dennis Huszar, and Denise C. Connolly

Biomarker Signatures Correlate with Clinical Outcome in Refractory Metastatic Colorectal Cancer Patients Receiving Bevacizumab and Everolimus
Yingmiao Liu, Mark D. Starr, John C. Brady, Christel Rushing, Anuradha Bultus, Herbert Pang, Wanda Honeycutt, Anthony Amara, Ivy Altmann, Hope E. Uronis, Herbert I. Hurwitz, and Andrew B. Nixon

Transcriptomic and Protein Expression Analysis Reveals Clinico-pathological Significance of Bloom Syndrome Helicase (BLM) in Breast Cancer
Arvind Arora, Tarek M.A. Abdel-Fatah, Devika Agarwal, Rachel Doherty, Paul M. Moseley, Mohammed A. Aleskandarny, Andrew R. Green, Graham Ball, Alaa T. Alshareeda, Emad A. Rakha, Stephen Y.T. Chan, Ian O. Ellis, and Srinivasan Madhusudan

Biomarker Signatures Correlate with Clinical Outcome in Refractory Metastatic Colorectal Cancer Patients Receiving Bevacizumab and Everolimus
Yingmiao Liu, Mark D. Starr, John C. Brady, Christel Rushing, Anuradha Bultus, Herbert Pang, Wanda Honeycutt, Anthony Amara, Ivy Altmann, Hope E. Uronis, Herbert I. Hurwitz, and Andrew B. Nixon
Polymorphic CAG Repeat and Protein Expression of Androgen Receptor Gene in Colorectal Cancer
Rui Huang, Guiyu Wang, Yanni Song, Feng Wang, Bing Zhu, Qingchao Tang, Zheng Liu, Yinggang Chen, Qian Zhang, Shan Muhammad, and Xishan Wang

Multifunctional Polymeric Micelles Co-loaded with Anti-Survivin siRNA and Paclitaxel Overcome Drug Resistance in an Animal Model of Ovarian Cancer
Giuseppina Salzano, Gemma Navarro, Malav S. Trivedi, Giuseppe De Rosa, and Vladimir P. Torchilin

 ABOUT THE COVER
Deregulation of cell-cycle checkpoints is a feature of many different cancer types. WEE1 kinase plays an important role in the maintenance of these cell-cycle checkpoints by inhibiting cyclin-dependent kinase (CDK) activity. Through siRNA screening, it was found that cancer cells with defects in Fanconi Anemia (FA) and homologous recombination pathways were more sensitive to WEE1 inhibition. The cover image shows that WEE1 inhibition in cells depleted of FA protein FANCM resulted in increased replication stress (pan-nuclear γH2AX staining in green) and premature entry into mitosis (yellow). Phospho-histone H3 staining (red) was used to identify mitotic cells. DNA was counterstained with DAPI (blue). For details, see the article by Aarts and colleagues on page 865.
Molecular Cancer Therapeutics

14 (4)


Updated version
Access the most recent version of this article at:
http://mct.aacrjournals.org/content/14/4

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.